Literature DB >> 3839867

Progress in the management of high risk non-Hodgkin's lymphomas. 10 years of experience of the 3rd Medical Department of Hanusch Hospital, Vienna.

R Heinz, H Hanak, A Stacher.   

Abstract

An analysis of 173 cases of non-Hodgkin's lymphoma (NHL) admitted to our hospital from January 1973 to January 1983 is presented. Of the 173 cases, 124 patients suffered from NHL of high grade malignancy according to the Kiel classification (37 centroblastic lymphoma (CB), 30 immunoblastic lymphoma (IB), 43 lymphoblastic lymphoma (LB), 14 NHL high grade malignancy unclassifiable). In addition, 26 patients with secondary high grade malignant NHL were included in the analysis (14 secondary CB, 10 secondary IB, 2 secondary LB). Also investigated were 23 patients with anaplastic centrocytic lymphoma (CC) (20 primary CC, 3 secondary CC), an entity originally classified as low grade malignant lymphoma, but showing a poor outcome and need for aggressive therapy. Symptoms at presentation of all patients are described. Of the 173 patients, 71% had an advanced stage of the disease at the time of diagnosis (Ann Arbor stage III or IV). B-symptoms were observed in 81%. Extranodal involvement, (exceptive bone marrow involvement), determined by clinical examination was seen in 55%. Survival of patients changed significantly after replacing initial radiotherapy with aggressive chemotherapy (P less than 0.001). Improvement of survival statistics was due to the better outcome of patients with localized stages (Ann Arbor stages I and II) as compared to those with generalized disease (P less than 0.002). Prognostic factors influencing survival were elevation of lactic dehydrogenase (P less than 0.0001) and response to therapy (P less than 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3839867     DOI: 10.1007/bf01732856

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  33 in total

1.  Treatment results of 54 American patients with Burkitt's lymphoma are similar to the African experience.

Authors:  J L Ziegler
Journal:  N Engl J Med       Date:  1977-07-14       Impact factor: 91.245

2.  Multivariate analysis of prognostic factors in the non-Hodgkin's malignant lymphomas.

Authors:  C D Bloomfield; A Goldman; F Dick; R D Brunning; B J Kennedy
Journal:  Cancer       Date:  1974-03       Impact factor: 6.860

3.  Chemotherapy of localised histiocytic lymphoma.

Authors:  T P Miller; S E Jones
Journal:  Lancet       Date:  1979-02-17       Impact factor: 79.321

4.  Occurrence and prognosis of extranodal lymphomas.

Authors:  C Freeman; J W Berg; S J Cutler
Journal:  Cancer       Date:  1972-01       Impact factor: 6.860

5.  [Extranodular manifestations of generalized malignant lymphomas].

Authors:  G Hajnos; M Pirovino; J R Rüttner
Journal:  Schweiz Med Wochenschr       Date:  1976-02-21

6.  [Retrospective analysis of the clinical relevance of the Kiel classification of malignant non-Hodgkin's lymphomas (author's transl)].

Authors:  G Brittinger; H Bartels; K Bremer; A Burger; E Dühmke; U Gunzer; E König; A Stacher; H Stein; H Theml; R Waldner
Journal:  Strahlentherapie       Date:  1977-04

7.  Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.

Authors:  R I Fisher; V T DeVita; S M Hubbard; D L Longo; R Wesley; B A Chabner; R C Young
Journal:  Ann Intern Med       Date:  1983-03       Impact factor: 25.391

8.  Primary gastrointestinal lymphoma: a 30-year review.

Authors:  D N Weingrad; J J Decosse; P Sherlock; D Straus; P H Lieberman; D A Filippa
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

9.  Prognostic significance of serum lactate dehydrogenase in malignant lymphoma.

Authors:  R J Schneider; K Seibert; S Passe; C Little; T Gee; B J Lee; V Miké; C W Young
Journal:  Cancer       Date:  1980-07-01       Impact factor: 6.860

10.  Malignant lymphoma. II Prognostic factors and response to treatment of 473 patients at the National Cancer Institute.

Authors:  T Anderson; V T DeVita; R M Simon; C W Berard; G P Canellos; A J Garvin; R C Young
Journal:  Cancer       Date:  1982-12-15       Impact factor: 6.860

View more
  1 in total

1.  Long-term follow-up of CHOP-treated non-Hodgkin lymphoma of high-grade malignancy.

Authors:  R Heinz
Journal:  Blut       Date:  1990-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.